ERBB2 and cancer: Our annotation of the pathway ‘Signaling by ERBB2 in Cancer’ (R-HSA-1227990), for example, illustrates the range of mechanisms by which normal ERBB2 signaling is disrupted and the types of small-molecule drugs that target these ERBB2 variants.